Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Enanta Pharmaceuticals Inc ENTA

Healthcare Biotechnology
Enanta Pharmaceuticals, Inc. is a clinical-stage biotechnology company dedicated to creating small molecule drugs with an emphasis on indications in virology and immunology. The Company's research and development programs are focused on respiratory syncytial virus (RSV) and chronic spontaneous urticaria (CSU). The Company discovered glecaprevir, the second of two protease inhibitors discovered... see more

Recent & Breaking News (NDAQ:ENTA)

Enanta Pharmaceuticals Provides Update on its Collaboration Agreement with AbbVie

Business Wire October 20, 2014

Enanta Pharmaceuticals Announces Data Presentations on Regimens Containing ABT-450 or ABT-493 to be Presented at the American Association for the Study of Liver Diseases (AASLD)

Business Wire October 1, 2014

AbbVie Demonstrates Commitment to Continued Research in Hepatitis C with Investigational Data from Clinical Program Being Presented at The Liver Meeting®

PR Newswire October 1, 2014

Enanta Regains Full Rights to NS5A Inhibitor EDP-239 for Hepatitis C Virus from Novartis

Business Wire October 1, 2014

Enanta Pharmaceuticals Announces the Initiation of Phase 2b Clinical Trial with Regimen Containing HCV Protease Inhibitor ABT-493

Business Wire September 10, 2014

Enanta Pharmaceuticals to Present at Three Upcoming Investor Conferences

Business Wire August 27, 2014

Enanta Pharmaceuticals Inc. (ENTA) Jumps 6.58% on August 26

Equities.com August 26, 2014

Enanta Pharmaceuticals Reports Financial Results for Its Fiscal Third Quarter Ended June 30, 2014

Business Wire August 11, 2014

Enanta Pharmaceuticals' HCV NS5A Inhibitor EDP-239 Advances into Combination Studies with Alisporivir (DEB025)

Business Wire August 7, 2014

Enanta Pharmaceuticals Announces European Medicines Agency Validates Marketing Authorization Applications for AbbVie's Investigational, All-Oral, Interferon-Free Regimen for Genotype 1 Chronic Hepatitis C

Business Wire June 17, 2014

European Medicines Agency Validates Marketing Authorization Applications for AbbVie's Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 1 Chronic Hepatitis C

PR Newswire June 17, 2014

Enanta Pharmaceuticals Announces U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Regimen for Genotype 1 Chronic Hepatitis C

Business Wire June 13, 2014

Enanta Pharmaceuticals to Present at Two Upcoming Investor Conferences

Business Wire June 10, 2014

Enanta Pharmaceuticals to Present at Jefferies 2014 Global Healthcare Conference

Business Wire May 22, 2014

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2014

Business Wire May 12, 2014

Enanta Pharmaceuticals Announces the Appointment of Nathaniel S. Gardiner, J.D. as Senior Vice President and General Counsel

Business Wire May 12, 2014

Enanta Pharmaceuticals Announces Submission of EU Marketing Authorization Applications to the European Medicines Agency for All-Oral, Interferon-Free Hepatitis C Regimen Containing ABT-450

Business Wire May 8, 2014

AbbVie Submits for EU Marketing Authorization its Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Chronic Hepatitis C

PR Newswire May 8, 2014

Enanta Pharmaceuticals to Present at the 39th Annual Deutsche Bank Securities Healthcare Conference

Business Wire April 30, 2014

Enanta Pharmaceuticals to Host Conference Call to Discuss Financial Results for the Fiscal Second Quarter and Six Months Ended March 31, 2014

Business Wire April 28, 2014